



Clinical Practice Guidelines: Toxicology and toxinology/Tricyclic antidepressants

Policy code	CPG_TO_TRA_0120
Date	January, 2020
Purpose	To ensure a consistent approach to the management of tricyclic antidepressants poisoning.
Scope	Applies to Queensland Ambulance Service (QAS) clinical staff.
Health care setting	Pre-hospital assessment and treatment.
Population	Applies to all ages unless stated otherwise.
Source of funding	Internal – 100%
Author	Clinical Quality & Patient Safety Unit, QAS
Review date	January, 2023
Information security	UNCLASSIFIED – Queensland Government Information Security Classification Framework.
URL	https://ambulance.qld.gov.au/clinical.html

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by QAS paramedics when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

© State of Queensland (Queensland Ambulance Service) 2020.



This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

Tricyclic antidepressant

January, 2020

Tricyclic antidepressants (TCAs) are potentially lethal in overdose.

TCA agents act on multiple receptor sites. Their principal antidepressant action is mediated by serotonin and norepinephrine re-uptake inhibition. Myocardial toxicity is via sodium channel blockade. Other toxicity is mediated by the inhibitory action at the muscarinic, histamine and adrenergic receptors. ^[1]

Tricyclic antidepressants are most commonly prescribed for depression, however also may be used in the treatment of chronic pain and migraine.

Tricyclic antidepressants include:

- Amitriptyline
- Clomipramine
- Dothiepin
- Doxepin
- Imipramine
- Nortriptyline

Clinical features



Anticholinergic effects

- Agitation/delirium
- Dilated pupils
- Dry, warm, flushed skin
- Hyperthermia
- Tachycardia
- Urinary retention

Neurotoxicity

- Sedation/Coma
- Seizures

Cardiotoxicity/ECG changes

- Hypotension
- Prolonged PR and QRS interval
- Prominent terminal R wave in aVR
- Ventricular tachycardia

Risk assessment



- Ingestions of more than 10 mg/kg in adults and 5 mg/kg in children are potentially toxic.^[2] Severe toxicity occurs with ingestions greater than 20 mg/kg.^[1]
- In large overdoses there can be a rapid, early deterioration with coma, seizures and cardiac arrhythmia
- All ingestions need review at a medical facility.

